1-3 of 3
Susan L. Paprcka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A011: Discovery and characterization of the first highly potent and selective AXL receptor tyrosine kinase inhibitor AB801

Free
Dillon H. Miles, Corinne N. Foley, Shiwei Qu, Dillon H. Miles, Srinivas Paladugu, Ehesan U. Sharif, Joice Thomas, Pradeep Nareddy, Guiling Zhao, Rebecca Grange, Manmohan R. Leleti, Jay P. Powers, Stefan Garrido-Shaqfeh, Ada Chen, Hema Singh, Yue Tong Lee, Xiaoning Zhao, David Green, Hsin-Ting Huang, Lixia Jin, Jhansi Leslie, Logan Chinn, Susan L Paprcka, Ester Fernandez-Salas
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (12_Supplement): A011.
https://doi.org/10.1158/1538-8514.CANCERCHEM24-A011
Published: 09 December 2024
View articletitled, Abstract A011: Discovery and characterization of the first highly potent and selective AXL receptor tyrosine kinase inhibitor AB801
Journal Articles

Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity

Open Access
Dana Piovesan, Joanne B.L. Tan, Annette Becker, Jesus Banuelos, Nell Narasappa, Daniel DiRenzo, Kristen Zhang, Ada Chen, Elaine Ginn, Akshata R. Udyavar, Fangfang Yin, Susan L. Paprcka, Bhamini Purandare, Timothy W. Park, Nikki Kimura, Jaroslaw Kalisiak, Stephen W. Young, Jay P. Powers, Uli Schindler, Kelsey E. Sivick, Matthew J. Walters
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 948–959.
https://doi.org/10.1158/1535-7163.MCT-21-0802
Published: 01 June 2022
View articletitled, Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
Open the PDF for Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

Abstract P253: Potent and selective AXL tyrosine kinase inhibition demonstrates significant anti-tumor efficacy in combination with standard of care therapeutics in preclinical models

Free
Susan L. Paprcka, Subhasree Sridhar, Irene M. Luu, Salema Jafri, Dillon H. Miles, Suan Liu, Ruben Flores, Shiwei Qu, Manjunath Lamani, Sriivas Paladugu, Cesar Meleza, James Wu, Hema Singh, Yu Chen, Sean Cho, Akshata Udyavar, Angelo Kaplan, Enzo Stargnaro, Xiaoning Zhao, Lixia Jin, Manmohan R. Leleti, Stephen W. Young, Jay P. Powers, Matthew J. Walters, Ester Fernandez-Salas
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P253.
https://doi.org/10.1158/1535-7163.TARG-21-P253
Published: 01 December 2021
View articletitled, Abstract P253: Potent and selective AXL tyrosine kinase inhibition demonstrates significant anti-tumor efficacy in combination with standard of care therapeutics in preclinical models